

0001598599-25-0000046-K Innate Pharma SA 2025011620250116081618081618081618 0 0001598599-25-000004 6-K
2 20250116 20250116 20250116 Innate Pharma SA 0001598599 2836 0000000000 IO 1231 6-K 34 001-39084 25534348
117 AVENUE DE LUMINY BP 30191 MARSEILLE IO 13009 33430303030 117 AVENUE DE LUMINY BP 30191
MARSEILLE IO 13009 Innate Pharma, SA 20140129 6-K 1 a6k-iphx250116.htm 6-K DocumentUNITED
STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-KREPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934Date of
report: January 16, 2025Commission File Number: 001-39084Innate Pharma S.A.(Translation of registrant's name into
English)Innate Pharma S.A.117 Avenue de Luminyâ€”BP 3019113009 Marseille, France+ 33 (0) 4 30 30 30(Address of
principal executive office)Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F. Form 20-F [X]A A A Form 40-F []INCORPORATION BY REFERENCEThis Report on Form
6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quotation from Johnathan Dickinson, Chief Executive
Officer and Chairman of the Executive Board of Innate Pharma S.A., the reference to the 43rd Annual J.P. Morgan
Healthcare Conference, and the related Internet link) shall be deemed to be incorporated by reference into the
registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-
282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a
part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports
subsequently filed or furnished.EXHIBIT INDEXExhibitA A A Description1.1A A A Press Release dated January 16,
2025SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.INNATE PHARMA S.A.Date:
January 16, 2025A A A By:A A A /s/ JONATHAN DICKINSONA A A Name:A A A Jonathan
DickinsonTitle:A A A Chairman of the Executive Board and Chief Executive Officer EX-99.1 2 exhibit991-2501101.htm
EX-99.1 DocumentEXHIBIT 99.1NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF
DECEMBER 31, 2024Marseille, France, January 16, 2025, 7:00 A.M. CETPursuant to the article L. 233-8 II of the
French â€œCode de Commerceâ€” and the article 223-16 of the French stock-market authorities (AutoritÃ© des
MarchÃ©s Financiers, or â€œAMFâ€”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(â€œInnateâ€” or the â€œCompanyâ€”) releases its total number of shares outstanding as well as its voting rights as of
December 31, 2024:Total number of shares outstanding:83,830,336 ordinary shares6,494 7,581 Preferred Shares
2016Preferred Shares 2017Total number of theoretical voting rights (1):Total number of exercisable voting rights (2):
84,585,57684,567,001(1) The total number of theoretical voting rights (or â€œgrossâ€” voting rights) is used as the
basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General
Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares
whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached
to AGAP 2016, i.e. 130A voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights
attached to AGAP 2017.(2) The total number of exercisable voting rights (or â€œnetâ€” voting rights) is calculated
without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so
as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July
17, 2007.About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage biotechnology company developing
immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three
therapeutic approaches: multi-specific NK Cell Engagers via its ANKETÃ© (Antibody-based NK cell Engager
Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies
(mAbs).Innateâ€”s portfolio includes several ANKETÃ© drug candidates to address multiple tumor types as well as
IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in
advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is
developed with AstraZeneca in non-small cell lung cancer.Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research
and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD,
Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at www.innate-
pharma.com and follow us on LinkedIn and X.Information about Innate Pharma shares:ISIN codeA :
FR0010331421Ticker codeA : Euronext: IPH Nasdaq: IPHALEIA : 9695002Y8420ZB8HJE29Disclaimer on forward-
looking information and risk factors: This press release contains certain forward-looking statements, including those
within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use
of certain words, including â€œanticipate,â€” â€œbelieve,â€” â€œcan,â€” â€œcould,â€” â€œestimate,â€” â€œexpect,â€”
â€œmay,â€” â€œmight,â€” â€œpotential,â€” â€œexpectâ€” â€œshould,â€” â€œwill,â€” or the negative of these and similar
expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are
based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated. These risks and uncertainties include,
among other things, the uncertainties inherent in research and development, including related to safety, progression of
and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory
authorities of its product candidates, the Companyâ€”s reliance on third parties to manufacture its product candidates,
the Companyâ€”s commercialization efforts and the Companyâ€”s continued ability to raise capital to fund its
development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from those contained in the forward-looking statements,
please refer to the Risk Factors (â€œFacteurs de Risque") section of the Universal Registration Document filed with the
French Financial Markets Authority (â€œAMFâ€”), which is available on the AMF website <http://www.amf-france.org> or
on Innate Pharmaâ€”s website, and public filings and reports filed with the U.S. Securities and Exchange Commission
(â€œSECâ€”), including the Companyâ€”s Annual Report on Form 20-F for the year ended December 31, 2023, and
subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the
Companyâ€”s website and the AMF website are included for information only and the content contained therein, or
that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press
release.In light of the significant uncertainties in these forward-looking statements, you should not regard these
statements as a representation or warranty by the Company or any other person that the Company will achieve its
objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or otherwise, except as required by
law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer

to buy or subscribe to shares in Innate Pharma in any country.For additional information, please
contact:Â Â Â Â InvestorsÂ Â Â Â Innate Pharma Â Â Â Â Henry Wheeler Â Â Â Â Tel.: +33 (0)4 84 90 32
88Â Â Â Â Henry.Wheeler@innate-pharma.frÂ Â Â Â Media RelationsNewCapArthur RouilleTel. : +33 (0)1 44 71 00
15innate@newcap.eu